Table 1.
Basic characteristics of breast cancer patients from the study sample
| Basic demographic & clinical characteristics | FEC (n = 73) | FEC-T (n = 60) | All regimens (n = 161) a |
|---|---|---|---|
| Age range (years) | 28-63 | 27-65 | 21-65 |
| Disease stage, n (%) metastatic | 12 (16) | 1 (2) | 20 (12) |
| Bone metastasis, n (%) | 7 (10) | 0 (0) | 12 (7) |
| HER status, n (%) positive | 17 (23) | 25 (42) | 53 (33) |
| Prior/concomitant surgery, n (%) | 67 (92) | 53 (88) | 145 (90) |
| Prior/concomitant radiotherapy, n (%) | 49 (67) | 40 (67) | 111 (69) |
| Prior/concomitant hormone therapy, n (%) | 42 (58) | 33 (55) | 90 (56) |
Basic demographic and clinical characteristics of the breast cancer patients are presented for the two most frequent chemotherapy regimens, and all regimens.
aOther regimens used in the sample but not displayed were docetaxel (n = 9), AC → T (n = 5), capecitabine/docetaxel (n = 2), capecitabine/docetaxel/trastuzumab (n = 2), docetaxel/trastuzumab (n = 2), epirubicin/cyclophosphamide (n = 2), FEC/trastuzumab (n = 2) and capecitabine/larotaxel, doxorubicin/docetaxel, epirubicin/docetaxel, epirubicin/cyclophosphamide/larotaxel (1 patient each)